2016
Drug‐resistant epilepsy in adults: Outcome trajectories after failure of two medications
Choi H, Hayat MJ, Zhang R, Hirsch LJ, Bazil CW, Mendiratta A, Kato K, Javed A, Legge AW, Buchsbaum R, Resor S, Heiman GA. Drug‐resistant epilepsy in adults: Outcome trajectories after failure of two medications. Epilepsia 2016, 57: 1152-1160. PMID: 27265407, DOI: 10.1111/epi.13406.Peer-Reviewed Original ResearchConceptsDrug-resistant epilepsySeizure freedomAntiepileptic drugsAdult patientsEpilepsy typeFocal epilepsyContinuous seizure freedomThird antiepileptic drugTertiary epilepsy centerSeizure-free periodMultiple ordinal logistic regression modelsLogistic regression modelsOrdinal logistic regression modelsClinical factorsIndependent predictorsEpilepsy centersMedical managementFluctuating courseOccipital lobeTemporal lobeEligibility criteriaPatientsEpilepsyTrajectory outcomesOutcome trajectories
2015
Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: An extended follow-up
Javed A, Cohen B, Detyniecki K, Hirsch LJ, Legge A, Chen B, Bazil C, Kato K, Buchsbaum R, Choi H. Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: An extended follow-up. Seizure 2015, 29: 34-40. PMID: 26076842, DOI: 10.1016/j.seizure.2015.03.013.Peer-Reviewed Original ResearchConceptsCognitive side effectsAntiepileptic medicationsSide effectsMultiple logistic regression analysisMore antiepileptic medicationsLogistic regression analysisQuality of lifeIndependent predictorsRetrospective studyAntiepileptic drugsAdult outpatientsMedical recordsAdverse effectsIntellectual disabilityPolytherapyLevetiracetamGabapentinRegression analysisLamotrigineLower ratesPredictorsCarbamazepineMonotherapyMedicationsRelative frequency
2012
Sudden unexpected death in epilepsy in lamotrigine randomized‐controlled trials
Tomson T, Hirsch LJ, Friedman D, Bester N, Hammer A, Irizarry M, Ishihara L, Krishen A, Spaulding T, Wamil A, Leadbetter R. Sudden unexpected death in epilepsy in lamotrigine randomized‐controlled trials. Epilepsia 2012, 54: 135-140. PMID: 23030403, DOI: 10.1111/j.1528-1167.2012.03689.x.Peer-Reviewed Original ResearchConceptsSudden unexpected deathProbable SUDEPTreatment armsAntiepileptic drugsClinical trialsOdds ratioUnexpected deathTonic-clonic seizure frequencyRate of SUDEPRisk of SUDEPRandomized clinical trialsRandomized-controlled trialPotential risk factorsCause deathPossible SUDEPStudy medicationPatient yearsSeizure frequencyTreatment deathsComparator armActive comparatorNonrandomized studyUnadjusted ratesComparator groupRisk factors
2008
Efficacy of Clobazam as Add-on Therapy for Refractory Epilepsy
Montenegro MA, Arif H, Nahm EA, Resor SR, Hirsch LJ. Efficacy of Clobazam as Add-on Therapy for Refractory Epilepsy. Clinical Neuropharmacology 2008, 31: 333-338. PMID: 19050410, DOI: 10.1097/wnf.0b013e31815cd960.Peer-Reviewed Original ResearchConceptsRefractory epilepsyEpilepsy centersColumbia Comprehensive Epilepsy CenterAntiepileptic drug regimenEfficacy of clobazamIntroduction of clobazamUS epilepsy centersUse of clobazamMultiple seizure typesComprehensive Epilepsy CenterAntiepileptic drug trialsPopulation of patientsAddition of clobazamMeasures of efficacyBinary logistic regressionDrug regimenSeizure freedomSeizure typesKaplan-MeierUS CentersDrug trialsPatientsUS FoodClobazamDrug Administration